T3 Companies’s Esperion Therapeutics ESPR Stock Holding History
Bought
Maintained
Sold
Other funds holding ESPR
T3 Companies's ESPR Position: Q3 2026 in Review
T3 Companies sold out of Esperion Therapeutics (ESPR) in Q3 2026, closing a stake of 82,500 shares — an estimated $261K sold.
T3 Companies first reported a position in ESPR in Q2 2026 and held it in 1 quarter. The position peaked at $261K in Q2 2026. 2 funds tracked by Wall St. Rank hold ESPR as of Q3 2026.
- T3 Companies reported no remaining Esperion Therapeutics position as of Q3 2026 after selling out during the quarter.
- T3 Companies sold 82,500 Esperion Therapeutics shares in Q3 2026, an estimated $261K.
- T3 Companies first reported a position in Esperion Therapeutics in Q2 2026 and held it in 1 quarter.
- T3 Companies's Esperion Therapeutics position peaked at $261K in Q2 2026.
- 2 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2026.
Based on T3 Companies's 13F filing for Q3 2026, filed 22 Oct 2026.